aTyr Pharma Announces One-for-40 Reverse Stock Split

aTyr Pharma (Nasdaq: ATYR), a clinical-stage biotechnology company, announced a 1-for-40 reverse stock split effective October 28, 2026, to comply with Nasdaq Capital Market's minimum bid price requirement. The split will reduce outstanding shares from approximately 100.5 million to 2.5 million, with trading resuming on a split-adjusted basis on October 29, 2026 under the same ticker symbol.